Key facts
- It has raised $140K; the latest was Later Stage VC in Feb 2025.
- Notable investors include Covirán, Fondation de l'Avenir, Genesis Biomed, Genesis Ventures, Medex Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Limnopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Limnopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Limnopharma
Developer of pharmaceutical research drugs designed to create new treatments for degenerative retinal disorders. The company offers small-molecule drug candidates derived from natural compounds with neuroprotective and anti-inflammatory properties, enabling patients with retinal diseases and ophthalmology specialists to access non-invasive therapeutic options that aim to preserve vision and improve long-term eye health.
- Sector
- Healthcare
- HQ
- Granada, Spain
- Founded
- 2019
- Website
- limnopharma.com/
- Ownership
- Privately Held (backing)
Limnopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Limnopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Limnopharma in its N-PORT filings yet. We sweep new filings monthly.